Autolus Therapeutics (AUTL)

• Market cap: $338M
• 1 day: -3.79%
• 5 days: -10.56%
• 1 month: -32.45%
• 3 months: -37.44%
• 6 months: -30.22%
• Year to date: -51.71%
• 1 year: -66.93%
• 5 years: -90.93%
• 10 years: -94.92%
• Sector: Healthcare
• Industry: Biotechnology

About: Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Employees: 647

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

50% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]

45% more capital invested

Capital invested by funds: $261M [Q1] → $378M (+$118M) [Q2]

28% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 25

0.78% less ownership

Funds ownership: 63.13% [Q1] → 62.35% (-0.78%) [Q2]

5% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 21

1% less funds holding

Funds holding: 94 [Q1] → 93 (-1) [Q2]

36% less call options, than puts

Call options by funds: $84K | Put options by funds: $131K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $5
• Avg. target: $7.5
• High target: $10

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Wells Fargo Yanan Zhu	$5	Overweight Maintained	13 Aug 2025
Needham Gil Blum	$10	Buy Reiterated	21 Jul 2025